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The future of renoprotection. Chronic kidney diseases are
emerging as a global threat to human health. Renal replace-
ment therapy by dialysis or renal transplantation prolongs sur-
vival in patients with end-stage renal disease (ESRD) and, in
most cases, provides a good quality of life. In all wealthy coun-
tries, new patients on dialysis outnumber those who die, and
the group of patients on renal replacement therapy is grow-
ing. The provision of adequate treatment to all is absorbing a
large proportion of the health care budget and is being looked
at with concern by policymakers. Because rationing of dialy-
sis or deciding that some patients cannot be treated is out of
the question, clinicians should be looking for ways to prevent
the need for dialysis in as many patients as possible. Simple
and inexpensive treatments are plausible and possibly effec-
tive. There is robust experimental evidence that proteinuria is
responsible for interstitial inflammation and subsequent fibro-
sis, which thereby contributes to progressive renal function loss.
Clinical studies and clinicopathologic correlations in patients
with progressive nephropathies indicate that observations in
experimental models are relevant to understanding human dis-
ease. Researchers have identified an important correlation be-
tween urinary protein excretion and rate of glomerular filtration
rate decline in patients with diabetic and nondiabetic chronic
nephropathy. Renoprotection is a strategy that aims to interrupt
or reverse this process. The current therapeutic approach for
proteinuric chronic nephropathies is based on blockade of the
renin-angiotensin system with angiotensin converting-enzyme
inhibitors and/or angiotensin-receptor blockers that limit pro-
teinuria, and reduce glomerular filtration rate decline and risk of
ESRD more effectively than other antihypertensive treatments.
Full remission of the disease, however, is seldom obtained, par-
ticularly when pharmacologic intervention is started late. For
those who do not respond, treatment procedures to achieve re-
mission and/or regression must include a multimodel strategy
to implement renoprotection. The role of lifestyle changes, in-
cluding smoking cessation, should not be overlooked. A more
concerted, strategic, and multisectorial approach, underpinned
by solid research evidence, is essential to help reverse the in-
creasing incidence of these chronic diseases, not just for a few
beneficiaries, but equitably and on a global scale.
Resumen
Las enfermedades renales cro´nicas se han constituido en una
seria amenaza global a la salud. La dia´lisis y el trasplante re-
nal prolongan la vida de los pacientes con insuficiencia renal
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cro´nica (IRC) y en su mayor parte, proveen de una buena cali-
dad de vida. En los paı´ses desarrollados el nu´mero de pacientes
nuevos en dia´lisis sobrepasa al de los que fallecen, por lo que
el nu´mero de pacientes en dia´lisis va en aumento. Es motivo de
preocupacio´n el que la provisio´n de un tratamiento adecuado a
todo aquel que lo necesita, este consumiendo un elevado por-
centaje de los presupuestos destinados a la atencio´n de la salud.
Dado de que esta´ fuera de consideracio´n el racionar o el decidir
que pacientes no reciban tratamiento dialı´tico, debemos de bus-
car las medidas necesarias que prevengan el uso de dia´lisis en
tantos pacientes como sea posible. Es factible y posible el uti-
lizar tratamientos sencillos y de bajo costo. Existe una so´lida
evidencia experimental de que la proteinuria es responsable
de la inflamacio´n y subsiguiente fibrosis del intersticio renal,
contribuyendo de esta forma al deterioro de la funcio´n renal.
Estudios clı´nicos realizados en pacientes con nefropatı´as pro-
gresivas, indican que las observaciones hechas en animales de
experimentacio´n son relevantes al estudio de la enfermedad
en humanos. Se ha encontrado una importante correlacio´n en-
tre la proteinuria y la disminucio´n en la velocidad de filtracio´n
glomerular, tanto en pacientes con nefropatı´a diabe´tica como
no diabe´tica. La renoproteccio´n es una estrategia dirigida a
interrumpir o revertir este proceso. El tratamiento actual de
las nefropatı´as cro´nicas se basa en el concepto de que la uti-
lizacio´n del bloqueo del sistema renina angiotensina con in-
hibidores de la ECA y/o bloqueadores del receptor de la an-
giotensina, disminuye la proteinuria, la perdida de la filtracio´n
glomerular y el riesgo de IRC, en forma ma´s efectiva que otros
fa´rmacos antihipertensivos. Sin embargo, rara vez se obtiene
una remisio´n total, especialmente si el tratamiento se inicia en
forma tardı´a. En individuos que no respondan a dicha terapia,
se debe de utilizar una estrategia de proteccio´n renal mu´ltiple.
Cambios en los ha´bitos de vida del individuo, incluyendo el
abandono del tabaco, no deben de ser pasados por alto. Un abor-
daje concertado, multifactorial y estrate´gico, sustentado por una
so´lida evidencia cientı´fica, es indispensable para revertir el in-
cremento en la incidencia de estas enfermedades cro´nicas, no
solo para el beneficio de unos cuantos, sino en una forma globaly
equitativa.
THE BURDEN OF CHRONIC RENAL DISEASES
Chronic kidney diseases are emerging as a global threat
to human health [1]. During the last decade, the dialysis
population has been growing at an average of 7% per
year. There are now approximately 1.1 million people
worldwide on renal replacement therapy (RRT) and, ac-
cording to reliable estimates, the number of patients on
maintenance dialysis will double in 10 years (Fig. 1). The
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Fig. 1. Global maintenance dialysis population from 1990 to 2010
(modified from [2]).
total cumulative cost for RRT in the next decade will
exceed US $1 trillion [2], a surprising figure from any
point of view. In the United States, the total Medicare
cost for dialysis and transplantation was US $12.7 billion
in 1999 and is expected to exceed US $28.3 billion in 2010.
Although this sum is 6% of the total Medicare budget,
it serves only 0.7% of the Medicare population. In the
European Union, the percentage of the health care ex-
penditure absorbed by RRT programs ranges from 0.7%
to 1.8%, whereas patients with end-stage renal disease
(ESRD) are 0.025% to 0.06% of the total population.
Continuing provision of adequate facilities, equipment,
and manpower to assist the growing number of patients
with ESRD will pose a substantial burden on health care
resources in all developed countries in the near future.
Thus, the cost and complexity of RRT put it out of reach
for low-income countries, which are struggling to provide
preventive and therapeutic measures for communicable
diseases such as malaria, tuberculosis, acquired immune
deficiency syndrome, and tropical disease infections, and
have to assign their meager budget to sanitation, vaccine,
nutrition, and other basic needs.
Contemporary treatment for ESRD is so costly that
there is little chance that the vast majority of the world’s
population will have access to it. Less-privileged coun-
tries simply cannot establish programs for regular RRT
for all patients with chronic kidney disease because of its
prohibitive cost [3].
How might the global burden of chronic kidney disease
be diminished in the future? At the present, there are no
definitive cures for most acquired kidney diseases, and
there is no reasonable expectation that gene therapy will
be available soon enough to treat genetic forms of kidney
diseases, such as polycystic kidney disease. Renal trans-
plantation is limited by organ shortage [4], a worldwide
problem that is not likely to be resolved by xenotrans-
plantation in the near or immediate future. The best we
can do at the present time is to concentrate our efforts on
the prevention of progression of renal diseases.
MECHANISMS OF RENAL DISEASE
PROGRESSION
During the last 20 years, research in animals and peo-
ple has helped our understanding of the mechanisms by
which chronic kidney diseases progresses and has in-
dicated possible preventive methods. A large number
of studies established that progressive deterioration of
renal function is the result of compensatory glomeru-
lar hemodynamic changes in response to nephron loss.
In a widely used experimental model of renal mass re-
duction, the remaining nephrons undergo hypertrophy,
reduced arteriolar resistance, and increased glomeru-
lar blood flow [5]. There is a lot of experimental and
clinical evidence that pharmacologic inhibition of renin-
angiotensin system with angiotensin-converting enzyme
(ACE) inhibitors or with angiotensin II subtype 1 recep-
tor antagonists (ARB) slow the progression of renal fail-
ure. In vivo, angiotensin II enhances the vascular tone of
both afferent and efferent glomerular arterioles and mod-
ulates intraglomerular capillary pressure and glomeru-
lar filtration rate (GFR) [6]. Aside from these glomeru-
lar hemodynamic effects of angiotensin II, other studies
have revealed several nonhemodynamic effects of an-
giotensin II that may also be important. These findings
have suggested that angiotensin II may alter permse-
lective properties of the glomerular capillary barrier by
mediating contraction of the foot processes, ultimately
changing slit-diaphragm architecture and allowing pro-
teins to escape more easily into the urinary space [7]. Ab-
normal protein trafficking through the glomerular capil-
lary wall might contribute to progression of renal dis-
ease. Indeed, recent data are in support of the possibil-
ity that the excessive protein load of podocytes can be a
factor underlying progressive injury of these glomerular
cells and through their release of transforming growth
factor b1, ultimately allowing myofibroblast differentia-
tion of mesangial cells [8]. Moreover, excessive protein
reabsorption by proximal tubuli provides further intrin-
sic toxicity to this nephron segment. Thus, both in vitro
and in vivo, protein overload causes increased produc-
tion of vasoactive and inflammatory mediators such as
endothelin-1, monocyte chemoattractant protein-1, nor-
mal T cell expressed and secreted, a chemotactic cytokine
for monocytes and memory T cells, and osteopontin [9].
The activation of a variety of molecules, such as cytokines,
growth factors, and vasoactive substances, may result in
abnormal accumulation of extracellular matrix collagen,
fibronectin, and other components that are responsible
for interstitial fibrosis. Proinflammatory mediators pro-
mote local recruitment of macrophages and lymphocytes
[10], which, in turn, can stimulate the transformation of
interstitial cells into myofibroblasts. Proximal tubular ep-
ithelial cells can interact with interstitial fibroblast to pro-
mote fibrogenesis via release of profibrogenic molecules
[11].
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Fig. 2. Pathophysiology of progressive
nephropathies.
In summary, there is robust experimental evidence that
proteinuria is responsible for interstitial inflammation
and subsequent fibrosis, thereby contributing to progres-
sive renal function loss (Fig. 2).
THE CONCEPT OF RENOPROTECTION
In chronic proteinuric nephropathies, if the interstitial
inflammatory reaction and subsequent fibrosis were in-
deed a feature of protein overloading, limiting protein
traffic or the biologic effect of excessive tubular protein
reabsorption should prevent or slow progression of renal
disease. This is precisely what happens in animals treated
with ACE inhibitors. The experimental demonstration
that the blockade of angiotensin II with ACE inhibitors
slowed the progressive loss of renal function in a num-
ber of animal models of renal diseases, including diabetic
nephropathy [12, 13], offered the opportunity, for the first
time, to devise a treatment strategy that was not limited to
passively accompanying patients to their destiny of dial-
ysis; instead, it was aimed at preserving renal function as
long as possible. The concept of renoprotection has thus
emerged.
The recent development of a new class of drugs, the
angiotensin-receptor blockers (ARBs) has offered a fur-
ther opportunity to improve renoprotection. The combi-
nation of 2 drugs, an ACE inhibitor and an ARB, in an ex-
perimental model of chronic nephropathy, was associated
with a significant reduction of proteinuria and a trend to-
ward less renal injury than with each drug alone [14].
The near-complete abolition of angiotensin II activity
is instrumental to achieve full renal protection. Clinical
studies and clinicopathologic correlations in patients with
progressive nephropathies indicate that observations in
experimental models are relevant to understanding hu-
man disease [15]. Researchers identified an important
correlation between urinary protein excretion and rate
of GFR decline in patients with diabetic [16] and nondi-
abetic chronic nephropathy [17]. The role of proteinuria
as a strong, independent predictor of ESRD has been re-
cently documented in a mass-screening setting [18]. By
screening more than 100,000 healthy patients in 1983 in
Okinawa, Japan, and following up with them for up to 17
years, a positive relationship was found between baseline
proteinuria (by dipstick urine test) and the risk for devel-
oping ESRD. Even a slight increase in proteinuria was an
independent risk factor for ESRD. Moreover, the predic-
tive value of the protein excretion rate was independent
of baseline GFR levels [19].
Whenever proteinuria is decreased, progression to
ESRD is reduced [20–23]. Results of the Modification
of Diet in Renal Disease study [20] established that a
reduction of proteinuria was associated with a decrease
in the rate of decline in GFR, and that protection of re-
nal function achieved by lowering blood pressure was
dependent on the extent of initial proteinuria. The role
of proteinuria as a promoter of progression and its im-
pact on renal outcome was also explored by the Ramipril
Efficacy in Nephropathy (REIN) study [23]. This study
was designed to assess the hypothesis that ACE inhibi-
tion might be superior to other antihypertensive drugs
in reducing proteinuria, limiting the decline in GFR, and
preventing ESRD in patients with chronic nephropathies.
In this study, patients were randomly assigned to re-
ceive ramipril or conventional antihypertensive therapy
to maintain diastolic blood pressure at 90 mm Hg or less.
A prestratification strategy recognized 2 levels of pro-
teinuria (stratum 1: >1 and <3 g/24 h; stratum 2: =3 g/24
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Lifestyle changes
Stop smoking, exercise, lower salt, protein, and calories
in diet, lose weight
Remission clinic
Targets of the multidrug approach:
Blood pressure  <120/80 mm Hg
Proteinuria  <0.3 g/24 h
LDL  <100 mg/dL
LDL + VLDL  <130 mg/dL
HbA1c  <75% (diabetics)
Fig. 3. Targets for the remission clinic for chronic nephropathies that
can be achieved by multidrug approach and lifestyle changes.
h). The study showed that although blood pressure con-
trol was similar in the 2 treatment groups, ACE inhibitor
therapy decreased the progression to ESRD by 50% [23,
24]. Patients who had more proteinuria to start with bene-
fited more from blood-pressure–lowering treatment than
those who had less proteinuria. A meta-analysis [25] in
1860 patients with chronic nephropathies also recorded
that the benefit of ACE inhibition was greatest in pa-
tients with high urine protein excretion at baseline. This
drug class seems to have a greater antiproteinuric effect
than other antihypertensive drugs, despite equal effects
on blood pressure; the investigators concluded that pro-
teinuria is the most important modifiable risk factor to
slow progression and that reduction of urine protein ex-
cretion is the main goal for treatment. The REIN study
was continued for 2 years (the REIN follow-up study),
during which all patients previously on placebo were
switched to ACE inhibitor [24]. In patients who contin-
ued to receive ramipril, GFR further decreased to ap-
proximately 0.1 mL/min/month during follow-up, a figure
similar to that associated with normal aging. Patients who
switched from conventional therapy to ramipril also ben-
efited from treatment. One of the most impressive find-
ings of this prolonged follow-up was that after about 36
months of treatment with ramipril, no additional patients
progressed to the point of requiring dialysis, whereas pa-
tients switched from conventional therapy to ramipril
continued to develop ESRD. A breakpoint was sought in
the individual GFR slopes of patients receiving contin-
ued ramipril therapy to further investigate the nature of
time-dependent improvement in GFR change. It could
be predicted that after the breakpoint, 10 patients re-
ceiving continued ramipril therapy would never progress
to ESRD and that those 10 patients had such improved
GFR slopes that progression to ESRD would be delayed
by about 5 years. The analysis provides evidence that the
tendency of GFR to decline with time can be halted, and
remission is achievable in some patients with chronic re-
nal disease.
The decade of large clinical trials in nephropathy was
closed when the results of 3 important studies were pub-
lished in the New England Journal of Medicine [26–28].
All 3 studies examined the role of ARBs in type 2 diabetic
nephropathy. One study evaluated the renoprotective ef-
fect of the ARB irbesartan in patients with hypertension
with incipient nephropathy [28]. The goal of the study was
the time of onset of overt albuminuria. In 2 years’ follow-
up, only 5.2% of patients receiving 300 mg of irbesartan
reached that goal, as compared with 14.9% of patients
on placebo. The groups had similar blood pressure con-
trol, a finding that suggests that ARBs are renoprotective
independently of their antihypertensive effect. The role
of ARB in overt diabetic nephropathy was explored in
2 other trials published in 2001 [26, 28]. In both studies,
treatment with ARB resulted in a significant reduction of
proteinuria, incidence of serum creatinine doubling, and
risk of ESRD.
Although we have limited our review to only a few
clinical studies, several other trials have been published,
some of them small, and with little statistical power and
short follow-up. However, they all point in one direc-
tion: blockade of renin-angiotensin system is beneficial
in most chronic nephropathies. This may not be true in
overt nephropathy of type 2 diabetes. The results of sev-
eral clinical trials have shown, with one exception, that
no significant difference was found in terms of renopro-
tection, as measured as prevention of GFR decline over
time, between ACE inhibitors and other antihyperten-
sive agents [29]. Indeed, in patients with type 2 diabetic
nephropathy, overt proteinuria, and renal insufficiency,
an ACE inhibitor was not able to modify renal hemody-
namics and glomerular-sieving properties, despite effec-
tive blood pressure control [30]. In summary, currently
available treatments have uniformly shown that reduc-
tion of blood pressure per se is beneficial in patients
with type 2 diabetic nephropathy, whereas the effect of
renin-angiotensin system blockade is probably less rele-
vant than in type 1 diabetic nephropathy or nondiabetic
nephropathies. Nevertheless, the results of the last decade
of experiments and trials provide an important platform
of knowledge to devise the best strategy in preventing
diabetic nephropathy in the next 10 years.
WHAT DOES THE FUTURE HOLD FOR
RENOPROTECTION?
Evidence from clinical trials suggests that the current
practice can, at best, postpone ESRD for a few years but
will not allow patients to avoid dialysis during their life-
time. Nevertheless, significant reduction of the incidence
of ESRD is likely to be achieved in the near future for
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nondiabetic chronic nephropathies, provided that we can
improve the degree of renoprotection. This goal may be
attainable with a more complex strategy than with a single
pharmacologic intervention.
By analogy with other major medical diseases (e.g.,
cancer, human immunodeficiency virus, and organ trans-
plantation), a multidrug intervention may be the strategy
needed to significantly retard dialysis [31]. Experimen-
tal data in rat models support this notion [14]. On clin-
ical grounds, there are a few trials that show that the
combination of an ACE inhibitor with an ARB affords
greater renoprotection than each drug used alone. Pre-
liminary studies in sodium-depleted healthy volunteers
and in patients with diabetes with normal renal function
recorded greater reduction in blood pressure and greater
increases in plasma renin activity after the addition of
losartan to enalapril treatment than after doubling the
dose of enalapril [32]. An additive antiproteinuric effect
of ACE inhibition and angiotensin II receptor antago-
nism has been reported in normotensive patients with im-
munoglobulin A nephropathy; systemic blood pressure
was not affected [33]. The COOPERATE study [34] com-
pared a combined treatment of ACE inhibitor and an-
giotensin II receptor blocker, with monotherapy of each
drug at its maximum dose, in patients with nondiabetic
renal disease. Eleven percent of patients on combina-
tion treatment reached the combined primary endpoint
of time to doubling of serum creatinine concentration or
ESRD compared with 23% of patients on trandolapril
alone (hazard ratio 0.38, 95% CI 0.18–0.63, P = 0.018)
and 23% of those on losartan alone (hazard ratio 0.40,
95% CI 0.17–0.69, P = 0.016). Concurrent diuretic ther-
apy will often be necessary in patients who already have
renal insufficiency, because fluid overload is an impor-
tant determinant of hypertension in this setting. If, after
this step, target blood pressure and proteinuria are not
achieved, the next antiproteinuric drug to be added is
usually a nondihydropyridinic calcium-channel blocker.
An abnormal lipid profile, besides accelerating
atherosclerosis, can promote progression of renal dis-
ease. Thus, in patients with serum low-density lipoprotein
(LDL) cholesterol >100 mg/dL, a statin may be added.
Moreover, in those with diabetes glycemic, control is re-
inforced to achieve hemoglobin A1c <7.5%. Both lipid
reduction and tight glycemic control are supposed to con-
tribute to renoprotection.
The multidrug approach to chronic nephropathies has
been formalized in an intervention protocol that has been
named “remission clinic” [35]. The protocol is targeted
to blood pressure <120/80 mm Hg, proteinuria <0.3 g/24
h, LDL <100 mg/dL, LDL + very LDL <130 mg/dL,
and hemoglobin A1c <7.5% (in patients with diabetes)
(Fig. 3). The multiple drug approach has been tested in
more than 40 patients in our unit, and we can show that
this is feasible and effective.
In looking for a more effective treatment, the role of
lifestyle changes should not be overlooked. Smoking ces-
sation per se may reduce disease progression by 30%,
which qualifies it as the single most important renopro-
tective measure [36]. Physical activity has always been
considered instrumental to the loss of excess weight, but
it may have an intrinsic favorable effect, as documented
by a small study in 20 patients with chronic kidney disease
who were assigned to 12-week regular aquatic exercise or
the armchair [37]. During this short period, the body mass
index did not change in either group. However, protein-
uria decreased by 50% in those who performed aquatic
exercise, whereas it did not change in the sedentary group.
The concept of a multidrug approach for renal disease
is extraordinarily reminiscent of the recent proposal of
Law et al [38] in the British Medical Journal to develop
a single pill containing aspirin, a statin, 3 antihyperten-
sive agents at half dose, and folic acid for the prevention
of cardiovascular disease. The “super pill” could indeed
be valuable, perhaps with some adjustments for patients
with chronic nephropathies. One of the potential advan-
tages of this “super pill” is that such an intervention could
be made available also to patients in poor countries.
RENOPROTECTION IN EMERGING COUNTRIES
The problem that we are facing now is whether this
approach is applicable to populations of middle- or low-
income countries. There are little and sparse data on the
incidence and prevalence of chronic kidney disease in
developing countries [39]. What is certain is that in all
low-income countries there are no dialysis facilities, or
not enough for all in need, and people still die of uremia.
Simple and inexpensive screening programs are feasible
at low cost in poor countries, and also simple and inex-
pensive treatments are plausible and possibly effective.
The Kidney Help Trust of Chennai, India [40] has em-
barked on a screening program in an area of 25,000 peo-
ple. Trained social and health workers recorded blood
pressure and checked for abnormal glucose levels and
for the presence of albumin in the urine. All those who
were positive for high blood pressure, diabetes, or both
were further studied and then treated with inexpensive
antihypertensive and antidiabetic drugs. The cost of a 1-
year program has been 300,000 Indian rupees (US $6500
per year); per capita costs were US $0.30, well within the
limit of Indian government per capita health expenditure
of US $8. Excellent blood pressure control was achieved
among patients with hypertension, whereas blood glu-
cose control in patients with diabetes was considered
good.
Another experience of mass screening for kidney
disease has been conducted, at very low cost, in Bo-
livia under the auspices of the International Society of
Nephrology-Commission for the Global Advancement of
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Nephrology [41]. More than 14,000 people were screened
for urinary abnormalities in 3 regions of Bolivia (urban,
mountain, and forest areas) by social workers. Some of
the patients who were found positive at first screening
were then enrolled in a follow-up program.
In Australia, a very successful program of detection
and treatment of renal and cardiovascular diseases in
Australian Aborigines has been conducted recently be-
tween 1995 and 2000 [42]. The treatment consisted of
long-acting ACE inhibitors targeted to lower blood pres-
sure. After an average of 3.4 years of follow-up, the inci-
dence of ESRD was reduced by 63% and nonrenal death
by 50%. From this study, it has been estimated that in
2 years this program may have saved from £800,000 to
£4.1 million in the costs of dialysis avoided or delayed.
Cost is the key factor to be considered here. A num-
ber of strategies, from discounted prices for medicine to
softening of patent protection and drug donation, have
been devised to increase the access to essential medicines
where they are most needed [43]. Much current think-
ing about how to direct resources of richer countries for
the benefit of the health of the developing world cen-
ters around government aid, tax incentives to encourage
the pharmaceutical industry to tackle some of its prob-
lems, the mobilization of earmarked funds by nongovern-
ment organizations, and hopes for further large dona-
tions from philanthropic bodies. Concern exists about
the efficiency, bureaucracy and, above all, sustainability
of many of these international sources of funding. An
attractive novel model to overcome these shortcomings
is—by analogy with the Global Fund to Fight AIDS, Tu-
berculosis and Malaria—to create a global fund for kid-
ney diseases. This should be coordinated by the Interna-
tional Society of Nephrology-Commission for the Global
Advancement of Nephrology and supported by resources
made available yearly from different institutions and or-
ganizations. An important contribution should be pro-
vided by national nephrology societies of Western coun-
tries. Also, pharmaceutical companies may be asked to
contribute support with donations to a global fund for
kidney disease. The sales of antihypertensive drugs and
especially ACE inhibitors have been very successful, and
these drugs give big returns to their manufacturers; a do-
nation of a small proportion of the overall revenues could
be taken in consideration. The contribution by the indus-
try to the fund for advancement of global health, even
with only a small part of the profit, could be negotiated
as a moral obligation.
The implementation of such an ambitious program can-
not be realized without the involvement of international
agencies such as the World Health Organization and the
World Bank. At the local level, it is important to establish
contacts with national scientific societies. Such contacts
are indispensable tools for health authorities and national
governments.
It is true that money is hard to find and when available
is always less than needed. However, the value of the
investment in renal prevention programs is astonishing.
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